Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. - Wikidata - wikimedia - TriplyDB

Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.

Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.

http://www.wikidata.org/entity/Q44510170

about

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort Factors associated with tobacco smoking and cessation among HIV-infected individuals under care in Rio de Janeiro, Brazil Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Risk stratification and prognosis of human immunodeficiency virus-infected patients with known or suspected coronary artery disease referred for stress echocardiography.Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort.Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).HIV as a risk factor for lung cancer in women: data from the Women's Interagency HIV Study Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study.Current cigarette smoking among HIV-positive current and former drug users: associations with individual and social characteristics.A Review of the Literature Concerning HIV and Cigarette Smoking: Morbidity and Mortality, Associations with Individual- and Social-Level Characteristics, and Smoking Cessation Efforts.Microbial translocation and cardiometabolic risk factors in HIV infection.Low HDL-cholesterol among HIV-1 infected and HIV-1 uninfected individuals in Nairobi, Kenya.Wellens syndrome in HIV-infected patients: Two case reports.HIV infection is associated with an increased risk for lung cancer, independent of smoking.The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.Tobacco use and its determinants in HIV-infected patients on antiretroviral therapy in West African countries Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy.Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients Tobacco smoking in HIV-infected versus general population in france: heterogeneity across the various groups of people living with HIV.Tobacco use and nicotine dependence among HIV-infected and uninfected injection drug users.Biomarkers and HIV-associated cardiovascular disease.T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis Cardiovascular implications from untreated human immunodeficiency virus infection.A Review of Carcinomas Arising in the Head and Neck Region in HIV-Positive Patients HIV infection in the etiology of lung cancer: confounding, causality, and consequences Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Comparison of Rates of Death Having any Death-Certificate Mention of Heart, Kidney, or Liver Disease Among Persons Diagnosed with HIV Infection with those in the General US Population, 2009-2011 Dyslipidemia and lipid management in HIV-infected patients Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study.Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort Epidemiology and management of antiretroviral-associated cardiovascular disease.HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction Management of dyslipidemia in HIV-infected patients.

P2860

Q24802369-CE9A5845-2FA8-431E-A3E4-C41934666E48 Q26753830-04B98F48-F843-45C0-8DFB-AB6FDD1CEE04 Q26777866-3B21D533-70FA-45C8-A010-9E123BF581E9 Q26851535-24872E52-F850-4151-AA94-F636D689AE99 Q27008328-ACD4B68E-DB8B-4164-8FB9-BDDE95A7B997 Q28479266-4A0F9D0E-E57E-4FD3-92F0-0139101206BE Q28541356-84A53D22-9A18-4BA8-B4BA-92A0DF427E88 Q28542839-C288028E-1D6E-4CEE-B724-B4247C5D352C Q30248286-B25BE48F-277C-458B-80DA-6498F913A129 Q30457521-845BAE8D-CAA2-42DD-97B6-AB8BB92ABE8A Q30593046-AF3EC42C-E145-4769-888B-C745CDD8814B Q33404972-E6FEF0B1-412C-4145-99CE-4C227F8EEDE0 Q33533549-FD21E301-9506-4E36-A52B-9B3E4E613793 Q33603728-078D8B87-A5C9-49C4-B653-2FCBB825C7CD Q33680718-78A6191E-4767-4643-9F3C-445D53BC3A85 Q33704159-0FE51624-453F-439A-8B4C-692AE20AD338 Q33713895-C12517DB-1DEE-4F34-8362-DE2B30B32E2B Q33785181-ABC59127-6AD5-4AAF-A122-D476B3C1C921 Q33818111-04744BF2-7FE1-497D-A9D1-5619E2A859BF Q33834602-FA405A7E-9C62-47AB-8344-285F2B541664 Q33889580-255F79CD-01DC-4522-967D-0CC66AA7C953 Q33907431-B978A9C7-73F6-4C96-8249-39CDA058EA93 Q33909483-0990F6D8-9390-474C-B315-E8F9C57EB6F7 Q34079798-2A406AE1-F8F1-4C69-8D66-3B016ED1E64F Q34156186-673487D1-E19B-4C5B-AB29-0C6D43C258EE Q34311573-5FC677CC-741C-4D9C-9892-F247F20C9D2F Q34335486-957019DD-0688-4AC6-A1B8-E293DE73FF00 Q34430776-277941EA-3255-4C35-94E8-43A82013CFA0 Q34793193-D46735E4-CE23-45F9-9DEA-B7DB7EB868B9 Q35025767-DB00EAD2-AF6B-4896-AE52-6A0CB6587E4F Q35095062-B1083454-821C-4C1E-BF85-0DA8F4698E35 Q35124939-9A1FB356-F5B3-4D37-8418-057DBE91AE6B Q35124958-AB2C1387-CDEF-4DDD-B629-4157E62438A9 Q35157763-0BF46945-DD97-4FF3-BFF2-1F712DFF368E Q35160574-6076B3F7-AC82-411B-B84A-213577147E65 Q35166149-28FF1EBD-7C14-4DB5-BBAC-A37471B8E824 Q35215672-D9D6FE95-4DD0-44B0-8234-26BF0BDE2319 Q35338096-E393D279-0820-4FCA-A801-FF5CB213666E Q35636087-B860BB1D-3DBE-4BF7-8BDF-36B21D8790C4 Q35643573-73AFE751-D2B3-483B-AAC8-CED65F655B22

P2860

Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.

http://www.wikidata.org/entity/Q44510170

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Risk factors for coronary hear ...... d with the general population.

@en

Risk factors for coronary hear ...... d with the general population.

@nl

type

label

Risk factors for coronary hear ...... d with the general population.

@en

Risk factors for coronary hear ...... d with the general population.

@nl

prefLabel

Risk factors for coronary hear ...... d with the general population.

@en

Risk factors for coronary hear ...... d with the general population.

@nl

P1433

Q44510170-42C31624-89C5-4A6B-8D1F-7EE1B189CFE7

P1476

Q44510170-99F1A8BD-35F9-484C-A335-ECBC48572F09

P2093

Q44510170-200EAED0-599C-479B-A4D7-335E51F2844F

Q44510170-52C9370C-909B-4D71-96DE-C8C55FE2ECE0

Q44510170-5E246C17-2A9A-4681-BCD2-9B02538C2A44

Q44510170-61C4E6E2-DDC9-425C-A4A5-3BF4EC38100F

Q44510170-9E913F99-D07D-4D9C-A88A-78CDEECC16A7

Q44510170-AD83813B-5E41-4138-A367-D9C084D999C8

Q44510170-EE09B0C7-744F-4C3D-BF7F-91E198EB067B

Q44510170-F327D5FD-972F-4707-A7E2-2EB413E4A631

Q44510170-FF1F5EA5-FE7D-4615-9F7C-E96EE1F8A03B

P2860

Q44510170-1839C623-5D62-41F0-B170-876C8CF634E2

Q44510170-398F7AA3-3024-4686-92AC-99BFB21A5C40

Q44510170-3F8D7ED5-4092-4734-8CA8-F62D494469EA

Q44510170-44C1DC1C-AB22-42E6-AF92-69E7FFEF1B00

Q44510170-5E11CA8C-3638-41C4-8C67-CE053C1A3231

Q44510170-6886E6DD-6C67-4EF9-87AB-26A5C46A3421

Q44510170-8847233F-E33D-43CF-A0D0-37B7A9CF627E

Q44510170-A800AE2B-880A-4B2C-8870-94F986B47E7F

Q44510170-AE95DF78-40FC-4F44-B621-862C64B1EF53

Q44510170-BE0F3C8B-AE10-4919-97A5-4A15FB1D9FFB

P304

Q44510170-D7204368-DA82-4DC1-B419-94D326A8C6C2

P31

Q44510170-A7945525-7527-4376-8C00-3B79D399DDD2

P356

Q44510170-CAD39CAC-187A-4740-AAD0-1A74EBD98F2D

P407

Q44510170-1105C0AD-5AA6-4A63-8B41-E9D77DC0FA98

P433

Q44510170-8E231A92-E89B-4C49-A19B-C813231F533D

P478

Q44510170-D0CCAE96-F922-43BC-80B5-D4D4D0863754

P50

Q44510170-94EAB4B1-6EFA-4C54-8FE8-DC0D2244C5CB

Q44510170-A28A2CA9-C5B2-45E9-A052-3C18D8937805

Q44510170-E3DC9799-ABC1-4637-8D5B-CC38EBAB575D

P577

Q44510170-7C94929F-B7F6-4B93-BBFB-5C8F9B2AABF8

P5875

Q44510170-23EFE7E3-EEC2-4BCA-8EC2-5315128701FD

P698

Q44510170-D54DFF2B-D7F5-486A-BE16-455CFFE92C80

P921

Q44510170-BAAED3B4-E763-476B-AC0D-89B387CC8BCD

P356

P1433

Clinical Infectious Diseases

P1476

Risk factors for coronary hear ...... d with the general population.

@en

P2093

Annie Bingham

http://www.w3.org/2001/XMLSchema#string

Catherine Leport

http://www.w3.org/2001/XMLSchema#string

Dominique Arveiler

http://www.w3.org/2001/XMLSchema#string

François Raffi

http://www.w3.org/2001/XMLSchema#string

French WHO MONICA Project and the APROCO (ANRS EP11) Study Group

http://www.w3.org/2001/XMLSchema#string

Gwenaël Le Moal

http://www.w3.org/2001/XMLSchema#string

Jacques Reynes

http://www.w3.org/2001/XMLSchema#string

Marianne Savès

http://www.w3.org/2001/XMLSchema#string

Pierre Ducimetière

http://www.w3.org/2001/XMLSchema#string

P2860

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations.

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy.

Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.

Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens.

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women.

Cardiovascular disease risk profiles.

P304

292-298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/375844

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Amouyel

Geneviève Chêne

Jean-Bernard Ruidavets

P577

2003-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10666189

http://www.w3.org/2001/XMLSchema#string

P698

12856222

http://www.w3.org/2001/XMLSchema#string

P921